Navigation Links
Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
Date:9/8/2009

DURHAM, N.C., Sept. 8 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced that it has formally notified Vatea Fund of the company's achievement of a milestone under the Securities Purchase Agreement dated June 8, 2009, as amended September 1, 2009. The milestone is a Clinical Trial for Oxycyte in Traumatic Brain Injury Approved by Swissmedic.

With the achievement of the milestone, the agreement calls for Vatea Fund to purchase 24 million shares of Oxygen Biotherapeutics stock from the company for $6 million with the transaction to close no later than December 10, 2009.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
2. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
3. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
4. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
5. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
6. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor ... global anti-obesity drugs market is expected to grow at a ... and CAGR of 38.7% in the second half of the forecast ... 32.8% from 2016 to 2027. The market is estimated at $1,058 ... 2027. ...
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
(Date:1/19/2017)... New Review of Safinamide ... Symptoms and Motor Complications in Mid- to Late-stage ... ... C Warren Olanow ... 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... ... WhoHaha , a digital media company dedicated to creating and delivering female-centric, comedic content, ... series that uses humor to highlight ways to improve heart health and overall well-being. ... movement, which is designed to inspire all Americans to make small changes that add ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. Andrew Lian-Jie ... fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research training at the ... internship in internal medicine at the Emory University and dermatology training at the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... for patients with sleep apnea and TMJ disorders. These conditions are quite common ... Dr. Rassouli provides personalized care to reduce the risk of these consequences and ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... asset protection and financial planning services to communities throughout eastern Georgia, is embarking ... against heart disease. , Heart disease kills more Americans every year than anything ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative ... Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries from ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer ...
Breaking Medicine News(10 mins):